Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Michel

Showing results (201-210 of 1,656) with videos related to

Pageof 166
Sort By:
Handbook of Experimental Pharmacology|July 13, 2023
Sex and Gender Differences in the Pharmacology of the Overactive Urinary BladderAndrea Pautz, Martin C Michel
European Urology|February 25, 2024
Re: Testosterone Treatment and Fractures in Men with HypogonadismHerbert Sperling, Martin C Michel
Expert Opinion on Drug Safety|March 9, 2016
Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studiesMartin C Michel, Stavros Gravas
European Urology|July 31, 2018
Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic HyperplasiaStephan Madersbacher, Martin C Michel
The Journal of Physiology|June 15, 1997
Differing effects of histamine and serotonin on microvascular permeability in anaesthetized ratsC C Michel, S Kendall
Expert Opinion on Therapeutic Targets|February 24, 2015
Therapeutic targets for overactive bladder other than smooth muscleMartin C Michel, Yasuhiko Igawa
Endocrinology|June 2, 1998
Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtypeA Bischoff, M C Michel
Handbook of Experimental Pharmacology|September 13, 2025
Biased Agonism at β-Adrenoceptor Subtypes: A Drug Development PerspectiveMartin C Michel, Ongun Onaran
Canadian Journal of Physiology and Pharmacology|March 29, 2000
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretionA Bischoff, M C Michel
Pediatric Blood & Cancer|January 31, 2019
ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effectsErica Brivio, C Michel Zwaan
Pageof 166

Showing results (201-210 of 1,656) with videos related to

Sort By:
Pageof 166
Handbook of Experimental Pharmacology|July 13, 2023
Sex and Gender Differences in the Pharmacology of the Overactive Urinary BladderAndrea Pautz, Martin C Michel
European Urology|February 25, 2024
Re: Testosterone Treatment and Fractures in Men with HypogonadismHerbert Sperling, Martin C Michel
Expert Opinion on Drug Safety|March 9, 2016
Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studiesMartin C Michel, Stavros Gravas
European Urology|July 31, 2018
Re: Tamsulosin and the Risk of Dementia in Older Men with Benign Prostatic HyperplasiaStephan Madersbacher, Martin C Michel
The Journal of Physiology|June 15, 1997
Differing effects of histamine and serotonin on microvascular permeability in anaesthetized ratsC C Michel, S Kendall
Expert Opinion on Therapeutic Targets|February 24, 2015
Therapeutic targets for overactive bladder other than smooth muscleMartin C Michel, Yasuhiko Igawa
Endocrinology|June 2, 1998
Neuropeptide Y lowers blood glucose in anaesthetized rats via a Y5 receptor subtypeA Bischoff, M C Michel
Handbook of Experimental Pharmacology|September 13, 2025
Biased Agonism at β-Adrenoceptor Subtypes: A Drug Development PerspectiveMartin C Michel, Ongun Onaran
Canadian Journal of Physiology and Pharmacology|March 29, 2000
Neuropeptide Y enhances potassium excretion by mechanisms distinct from those controlling sodium excretionA Bischoff, M C Michel
Pediatric Blood & Cancer|January 31, 2019
ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effectsErica Brivio, C Michel Zwaan
Pageof 166